We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IQV:NYSEIQVIA Holdings, Inc. Analysis

Data as of 2026-09-03 - not real-time

$263.84

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

IQVIA Holdings Inc. is priced at $263.84 and its moving averages line up in bullish order, the shorter sitting above the longer. Over a rolling month the price has gained 32.9%. Momentum indicators put RSI at 70.8 (overbought) with MACD reading bearish. The recent range runs from support at $228.76 up to resistance at $266.08.
Multiples put this in overvalued territory: 32.1 times earnings against the sector's 30.8. Analyst price targets sit 4.7% above the current price. Revenue is growing at 8.7% on a 8.1% profit margin.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 47.3%, a beta of 0.78 and a maximum drawdown of 35.9%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top Market Events

In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global...Clinical research company IQVIA NYSE: IQV in Q2 CY2026, with sales up 8.IQVIA Holdings Inc. NYSE:IQV extended its winning streak to a 4th straight session on Tuesday, jumping 13.94 percent to...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • RSI at 70.8 signals overbought conditions
  • Trading above the 200-day average of 201.37

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • RSI at 70.8 signals overbought conditions
  • P/E of 32.1 versus sector average of 30.8

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 32.1 versus sector average of 30.8
  • Return on equity of 22.8%
  • Elevated debt-to-equity of 258

Key Metrics & Analysis

Financial Health

Revenue Growth8.70%
Profit Margin8.10%
P/E Ratio32.1
ROE22.82%
ROA5.06%
Debt/Equity257.98
P/B Ratio7.0
Op. Cash Flow$2.8B
Free Cash Flow$2.1B
Industry P/E30.8

Technical Analysis

TrendBullish
RSI70.8
Support$228.76
Resistance$266.08
MA 20$250.60
MA 50$226.78
MA 200$201.37
MACDBearish
VolumeIncreasing
Fear & Greed Index94.29

Valuation

Fair Value$151.96
Target Price$276.28
Upside/Downside4.71%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.78
Volatility47.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.